Future Directions

Future Directions

The 2018 Farm Bill was signed on December 20th of that year. It removed hemp from the controlled substance act; this means that cannabis plants and derivatives that “contain no more than 0.3% THC on dry weight basis are no longer controlled substances under the law.” To date one of the challenges facing all Cannabis products was that the Schedule 1 designation made clinical investigation a nearly insurmountable challenge. Although THC remains a schedule 1 product, some loosening of the regulation on CBD may allow for further studies.

At the same time, the Farm Bill clearly preserved the FDA’s right to regulate all cannabis derived products. Only one CBD based medication, Epidiolex, for a specific seizure disorder has been approved by the FDA. They have clearly stated that selling products with unsubstantiated claims is against the law.

Gaining FDA approval for a specific product and diagnosis is a very lengthy and costly process. It is not highly likely that any single producer will have the incentive to do this unless they can some patented protection. With time however, it is hoped that we will gain more knowledge as to the benefits of CBD. This will rely on companies making consistent and validated products.

Sol Santa Fe is establishing a scientific board principally made up of practicing physicians to assess the growing body of investigation and literature we hope to be able to play a role in the fundamental gains in knowledge in this very exciting arena.